EGFR/ErbB1/HER1

EGFR/ErbB1/HER1 is an ErbB/HER receptor protein-tyrosine kinase that links extracellular growth-factor recognition to intracellular signaling through a ligand-binding ectodomain, transmembrane segment, catalytic kinase domain, and tyrosine-containing cytoplasmic tail^[1]. Mechanistically, ligand-stabilized receptor dimerization activates kinase signaling, trans-autophosphorylation, and downstream pathways that regulate mammalian cell growth, survival, proliferation, and differentiation^[1][2]. In cancer models, ErbB1 and ErbB2 are overexpressed in tumors including breast, colorectal, ovarian, and non-small-cell lung cancers, making EGFR signaling a practical axis for tumor biology experiments^[1]. Compared with related isoforms, ErbB1 and ErbB4 bind EGF-family ligands, whereas ErbB2 is an orphan co-receptor and ErbB3 lacks tyrosine kinase activity^[3]. EGFR and ErbB2 also couple to distinct mitogenic signaling pathways, supporting isoform-specific experimental design^[4]. For inhibitor studies, EGFR-TKIs such as erlotinib, gefitinib, afatinib, and icotinib are used in EGFR-mutated advanced NSCLC, where meta-analysis reported superior response and one-year progression-free survival versus chemotherapy^[5]. In EGFR-positive experimental systems, ZD1839 blocked EGFR autophosphorylation and EGF-induced PLC-γ1, ERK MAPK, and PKB/Akt activation, supporting pathway-level pharmacologic interrogation^[6].